LXRX logo

Lexicon Pharmaceuticals (LXRX) Operating Expenses

Annual Operating Expenses

$172.87 M
+$71.97 M+71.33%

December 31, 2023

Summary

Performance

1-Year Change

+71.33%

3-Year Change

-13.93%

5-Year Change

+5.41%

15-Year Change

-20.82%

LXRX Operating Expenses Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

69.53%
LXRX annual total operating expenses is higher than 69.53% of companies in Healthcare sector

High & Low

All-time High

$218.31 M
LXRX annual total operating expenses is currently -20.82% below its historical high of $218.31 million

3-Year Low

$87.39 M
LXRX annual total operating expenses is currently +97.82% above its 3-year low

Earnings dates

Last Annual Earnings Report Date

Dec 31, 2023
LXRX previous annual earnings announcement was published on Dec 31, 2023

Next Annual Earnings Report Date

May 2, 2025
LXRX next annual earnings announcement is scheduled for May 2, 2025

OtherLXRXexpensesmetrics:

Annual Total Expenses

$172.95 M
LXRX annual total expenses is $172.95 million

Annual Interest Expense

$13.10 M
LXRX annual interest expense is $13.10 million

Annual Income Tax

-
LXRX annual income tax value is unknown

Annual Cost Of Goods Sold

$85.00 K
LXRX annual cost of goods sold is $85.00 thousand

Quarterly Operating Expenses

$65.37 M
+$8.54 M+15.02%

September 30, 2024

Summary

Performance

3-Month Change

+15.02%

1-Year Change

+40.79%

3-Year Change

+182.58%

5-Year Change

+61.19%

LXRX Quarterly Operating Expenses Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Sector Rank

75.76%
LXRX quarterly total operating expenses is higher than 75.76% of companies in Healthcare sector

High & Low

All-time High

$71.41 M
LXRX quarterly total operating expenses is currently -8.46% below its historical high of $71.41 million

3-Year Low

$23.13 M
LXRX quarterly total operating expenses is currently +182.58% above its 3-year low

Earnings dates

Last Quarterly Earnings Report Date

Sep 30, 2024
LXRX previous earnings announcement was published on Sep 30, 2024

Next Quarterly Earnings Report Date

May 2, 2025
LXRX next earnings announcement is scheduled for May 2, 2025

OtherLXRXexpensesmetrics:

Quarterly Total Expenses

$65.44 M
LXRX quarterly total expenses is $65.44 million

Quarterly Interest Expense

$4.56 M
LXRX quarterly interest expense is $4.56 million

Quarterly Income Tax

-
LXRX quarterly income tax value is unknown

Quarterly Cost Of Goods Sold

$71.00 K
LXRX quarterly cost of goods sold is $71.00 thousand

Operating Expenses Formula

Operating Expenses = Selling, General & Administrative (SG&A) Expenses + Research & Development (R&D) Expenses + Depreciation & Amortization + Other Operating Expenses

Annual Operating Expenses

$172.87 M
LXRX annual total operating expenses is $172.87 million

Annual SGA

$113.98 M
LXRX annual SGA is $113.98 million

Annual D&A

$554.00 K
LXRX annual depreciation & amortization is $554.00 thousand

LXRX Operating Expenses Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterly
1 y1 year+71.3%+40.8%
3 y3 years-13.9%+182.6%
5 y5 years+5.4%+61.2%

LXRX Operating Expenses Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs low
3 y3-yearat high+97.8%at high+182.6%
5 y5-year-13.9%+97.8%-8.5%+780.5%
alltimeall time-20.8%+786.5%-8.5%+1140.5%

Lexicon Pharmaceuticals Operating Expenses History

DateAnnualQuarterly
Sep 2024
-
$65.37 M(+15.0%)
Jun 2024
-
$56.84 M(+22.4%)
Mar 2024
-
$46.43 M(-2.0%)
Dec 2023
$172.87 M(+71.3%)
$47.37 M(-4.9%)
Sep 2023
-
$49.79 M(+11.8%)
Jun 2023
-
$44.55 M(+42.9%)
Mar 2023
-
$31.17 M(+2.8%)
Dec 2022
$100.90 M(+15.5%)
$30.31 M(+31.0%)
Sep 2022
-
$23.13 M(-3.8%)
Jun 2022
-
$24.04 M(+2.7%)
Mar 2022
-
$23.42 M(-7.6%)
Dec 2021
$87.39 M(-56.5%)
$25.34 M(+10.3%)
Sep 2021
-
$22.98 M(+26.3%)
Jun 2021
-
$18.19 M(-12.8%)
Mar 2021
-
$20.87 M(+181.1%)
Dec 2020
$200.85 M(+35.0%)
$7.42 M(-85.8%)
Sep 2020
-
$52.14 M(-27.0%)
Jun 2020
-
$71.41 M(+2.2%)
Mar 2020
-
$69.87 M(+26.6%)
Dec 2019
$148.76 M(-9.3%)
$55.17 M(+36.0%)
Sep 2019
-
$40.56 M(+50.8%)
Jun 2019
-
$26.90 M(+2.9%)
Mar 2019
-
$26.13 M(-9.5%)
Dec 2018
$164.00 M(-24.9%)
$28.87 M(-1.6%)
Sep 2018
-
$29.34 M(-32.1%)
Jun 2018
-
$43.23 M(-30.9%)
Mar 2018
-
$62.55 M(+6.8%)
Dec 2017
$218.31 M(+5.4%)
$58.59 M(+4.9%)
Sep 2017
-
$55.86 M(+23.0%)
Jun 2017
-
$45.41 M(-22.3%)
Mar 2017
-
$58.45 M(+45.0%)
Dec 2016
$207.13 M(+74.0%)
$40.30 M(-37.8%)
Sep 2016
-
$64.80 M(+14.4%)
Jun 2016
-
$56.63 M(+24.7%)
Mar 2016
-
$45.40 M(+23.1%)
Dec 2015
$119.02 M(+9.5%)
$36.89 M(+29.5%)
Sep 2015
-
$28.49 M(+5.2%)
Jun 2015
-
$27.08 M(+1.9%)
Mar 2015
-
$26.57 M(+10.6%)
Dec 2014
$108.69 M(+1.8%)
$24.02 M(-16.4%)
Sep 2014
-
$28.73 M(+9.1%)
Jun 2014
-
$26.34 M(-11.0%)
Mar 2014
-
$29.61 M(+25.1%)
Dec 2013
$106.80 M(+7.2%)
$23.68 M(-21.4%)
Sep 2013
-
$30.12 M(+6.2%)
Jun 2013
-
$28.36 M(+15.1%)
Mar 2013
-
$24.65 M(-1.0%)
Dec 2012
$99.62 M
$24.91 M(+5.6%)
Sep 2012
-
$23.59 M(+0.3%)
Jun 2012
-
$23.52 M(-14.8%)
DateAnnualQuarterly
Mar 2012
-
$27.60 M(+2.5%)
Dec 2011
$109.18 M(+11.5%)
$26.92 M(+3.4%)
Sep 2011
-
$26.05 M(-1.6%)
Jun 2011
-
$26.48 M(-10.9%)
Mar 2011
-
$29.73 M(+41.8%)
Dec 2010
$97.92 M(-2.7%)
$20.97 M(-16.2%)
Sep 2010
-
$25.03 M(-1.1%)
Jun 2010
-
$25.31 M(-4.9%)
Mar 2010
-
$26.61 M(+14.4%)
Dec 2009
$100.66 M(-21.9%)
$23.26 M(-2.6%)
Sep 2009
-
$23.89 M(-7.3%)
Jun 2009
-
$25.77 M(-7.1%)
Mar 2009
-
$27.74 M(+1.8%)
Dec 2008
$128.86 M(+3.0%)
$27.24 M(-15.8%)
Sep 2008
-
$32.33 M(-10.1%)
Jun 2008
-
$35.95 M(+7.9%)
Mar 2008
-
$33.33 M(+3.3%)
Dec 2007
$125.07 M(-2.3%)
$32.27 M(+9.0%)
Sep 2007
-
$29.61 M(-3.2%)
Jun 2007
-
$30.60 M(-6.1%)
Mar 2007
-
$32.59 M(+6.4%)
Dec 2006
$128.03 M(+14.5%)
$30.64 M(-5.2%)
Sep 2006
-
$32.32 M(-2.4%)
Jun 2006
-
$33.10 M(+3.5%)
Mar 2006
-
$31.98 M(+13.5%)
Dec 2005
$111.80 M(+2.4%)
$28.17 M(+0.5%)
Sep 2005
-
$28.02 M(-1.4%)
Jun 2005
-
$28.42 M(+4.5%)
Mar 2005
-
$27.19 M(-1.0%)
Dec 2004
$109.19 M(+3.6%)
$27.47 M(+1.5%)
Sep 2004
-
$27.06 M(-0.6%)
Jun 2004
-
$27.22 M(-0.8%)
Mar 2004
-
$27.45 M(+5.4%)
Dec 2003
$105.43 M(+7.5%)
$26.04 M(-3.5%)
Sep 2003
-
$26.98 M(+0.8%)
Jun 2003
-
$26.77 M(+4.4%)
Mar 2003
-
$25.64 M(+3.8%)
Dec 2002
$98.09 M(+32.2%)
$24.70 M(-3.1%)
Sep 2002
-
$25.50 M(+1.8%)
Jun 2002
-
$25.05 M(+9.7%)
Mar 2002
-
$22.83 M(-0.3%)
Dec 2001
$74.22 M(+48.6%)
$22.90 M(+6.8%)
Sep 2001
-
$21.45 M(+36.3%)
Jun 2001
-
$15.74 M(+11.4%)
Mar 2001
-
$14.13 M(-325.0%)
Dec 2000
$49.94 M(+156.1%)
-$6.28 M(-144.1%)
Sep 2000
-
$14.26 M(+12.0%)
Jun 2000
-
$12.73 M(-56.5%)
Mar 2000
-
$29.24 M
Dec 1999
$19.50 M
-

FAQ

  • What is Lexicon Pharmaceuticals annual total operating expenses?
  • What is the all time high annual operating expenses for Lexicon Pharmaceuticals?
  • What is Lexicon Pharmaceuticals annual operating expenses year-on-year change?
  • What is Lexicon Pharmaceuticals quarterly total operating expenses?
  • What is the all time high quarterly operating expenses for Lexicon Pharmaceuticals?
  • What is Lexicon Pharmaceuticals quarterly operating expenses year-on-year change?

What is Lexicon Pharmaceuticals annual total operating expenses?

The current annual operating expenses of LXRX is $172.87 M

What is the all time high annual operating expenses for Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals all-time high annual total operating expenses is $218.31 M

What is Lexicon Pharmaceuticals annual operating expenses year-on-year change?

Over the past year, LXRX annual total operating expenses has changed by +$71.97 M (+71.33%)

What is Lexicon Pharmaceuticals quarterly total operating expenses?

The current quarterly operating expenses of LXRX is $65.37 M

What is the all time high quarterly operating expenses for Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals all-time high quarterly total operating expenses is $71.41 M

What is Lexicon Pharmaceuticals quarterly operating expenses year-on-year change?

Over the past year, LXRX quarterly total operating expenses has changed by +$18.94 M (+40.79%)